Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

What does the research say about neuroinflammation?

Neuroinflammation is a broad term for inflammatory signalling in the central nervous system. This page summarises what published research reports about its mechanisms and the compounds studied in laboratory and animal mo

peptides-pro Editorial

What is neuroinflammation?

Neuroinflammation is the formal term for the inflammatory response mounted within the central nervous system. It is not a single molecule and has no sequence, formula or molecular weight; it is a class of processes involving resident glial cells, cytokines, chemokines and peripheral immune cell infiltration. The term is used across traumatic brain injury, neurodegenerative disease, ischemic injury, metabolic disease and neonatal encephalopathy.

The work summarised here centres on the NLRP3 inflammasome and the AMPK signalling pathway, with additional evidence on NMDA receptor blockade, NAD+ homeostasis, and astrocytic and microglial regulation.

Research Studies

AMPK activators and NLRP3 inflammasome-mediated neuroinflammation in a rat weight-drop model

A study in Sprague-Dawley rats used a weight-drop model of traumatic brain injury (TBI) to examine whether AMPK activation suppresses NLRP3 inflammasome-mediated neuroinflammation. TBI was reported to disrupt AMPK signalling, impair energy homeostasis and activate inflammatory pathways. The AMPK activators examined were metformin, quercetin, resveratrol, cinnamaldehyde and berberine. The authors stated that the role of these compounds in modulating the NLRP3 inflammasome in TBI-induced neuroinflammation remained unclear before the study [3].

Magnesium sulphate and NMDA receptor blockade in neonatal asphyxia

A randomised controlled trial evaluated adjuvant intravenous magnesium sulphate in term neonates with birth asphyxia. The rationale given is that intravenous magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. The trial administered 250 mg/kg within 6 hours of birth and assessed duration of hospital stay and short-term clinical outcomes. The setting described is resource-limited, where therapeutic hypothermia is unavailable [1].

Tauroursodeoxycholate and liver-targeted therapy in diabetic macular edema

A clinical trial protocol describes an integrative liver-targeted approach to diabetic macular edema using tauroursodeoxycholate, a bile acid, or traditional Chinese medicine. The background states that diabetic macular edema cannot be managed without addressing systemic inflammation, and that hepatic metabolic dysfunction has been linked to the neuroinflammation and vascular dysfunction observed in diabetic retinopathy. Conventional therapies are described as providing transient visual improvement and being uncomfortable and financially burdensome [2].

Oxiracetam in neurocognitive disorders

A narrative review evaluated the mechanistic basis, clinical efficacy and safety profile of oxiracetam across neurological disorders including aging-related cognitive impairment, neurodegenerative disease, stroke and traumatic brain injury. The review notes that existing pharmacological treatments such as cholinesterase inhibitors and memantine provide limited and variable benefit. Mechanistic studies assessing pharmacodynamics, including cholinergic effects, were synthesised alongside preclinical and clinical literature [6].

NMNAT-1 and NAD+ homeostasis in neuroprotection

A review examined nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1), which catalyses the final step in NAD+ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family. NAD+ is described as a metabolic cofactor supporting redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation and neuronal maintenance. Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, though the review notes that the causal node and limiting compartment differ across tissues and disease states. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited disease [7].

Coenzyme Q10 and sevoflurane-induced neuroinflammation in mouse hippocampal neurons

A study reported that coenzyme Q10 alleviated sevoflurane-induced neuroinflammation by regulating apolipoprotein E and phosphorylated tau in mouse hippocampal neurons. A corrigendum subsequently stated that the authors had used an inappropriate antibody: an antibody against PHD finger protein 1 was used to probe tau paired helical filaments, when the intention was to detect tau phosphorylation at Ser396/404. The authors acknowledged a methodological error affecting the western blot results [8].

Natural medicines for Alzheimer's disease: bibliometric and narrative synthesis

A bibliometric analysis and narrative review mapped research on natural medicines for Alzheimer's disease using Web of Science Core Collection publications from 1 January 2001 to 28 April 2025, analysed with VOSviewer and CiteSpace. The authors noted that the relationship between bibliometric themes and experimental evidence had been insufficiently characterised, and used the bibliometric findings to guide a focused narrative synthesis of original experimental studies [4].

Nutritional paradox in uremia and systemic anabolic resistance

A framework paper proposed a "sensitize-then-feed" model for protein-energy wasting in advanced chronic kidney disease. The authors describe a nutritional paradox in which a subset of uremic patients do not respond to caloric and protein supplementation as in simple starvation. CKD-associated cachexia is characterised by potential systemic anabolic resistance, rendering oral supplements and intradialytic parenteral nutrition often insufficient. The paper proposes a molecular hierarchy driving this barrier [5].

Reference-only findings

Additional papers support the broader picture without forming the basis of a section. A system-level model of Parkinson's disease positions astrocyte dysfunction, or astrocytopathy, as a central and active driver of pathogenesis, extending the disorder beyond a purely neurodegenerative framing to a multicellular failure of the neuroglial unit [9]. A study of bilirubin encephalopathy reported that unconjugated bilirubin-induced neuroinflammation plays a pivotal role in pathogenesis and progression, and examined microglial lipophagy via the AMPK-mTOR signalling pathway [10]. A triangulation study using in silico, proteomics and experimental validation examined the neuroprotective mechanisms of pterostilbene in hyperhomocysteinemia-induced cognitive impairment [11]. A study of ischemic cerebral injury found that the E3 SUMOylase TRIM28 SUMOylates IRF3 in astrocytes to drive neutrophil infiltration [12].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp